The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes.
Sparsentan is an investigational small molecule candidate designed to selectively block the receptors of endothelin type A and angiotensin II type I, which are associated with kidney disease progression.
Peripheral lymphatic vessels may not compensate for interstitial accumulation and fluid extravasation in HFpEF.
Greatest CAN prevention effect seen among type 2 diabetes patients without cardiovascular disease history.
In a trial of patients with primary membranous nephropathy, corticosteroid-cyclophosphamide induced significantly more and faster remission of nephrotic syndrome than tacrolimus-rituximab.
Severe renal arteriosclerosis in diagnostic lupus nephritis biopsies is associated with 9-fold higher odds of atherosclerotic cardiovascular disease.
Pooled relative risk of 0.988 for each increment of one cup of coffee per day revealed in meta-analysis of cohort studies
Study authors evaluated patient perspectives to inform the voting process for the 2020 American College of Rheumatology gout treatment guideline.
Older patients have lower mobile health proficiency, as do those with Hispanic/Latinx ethnicity, less than college education
6.8% of those undergoing noncardiac surgery from January 2013 to December 2017 had preoperative natriuretic peptide screening